SS 42 - Advanced Lung Cancer and Drug Combinations

Presentations

• 12:30pm - 12:40pm ET

  A Prospective, Randomized Controlled Study on the Time Window of Radiotherapy Combined with Targeted Therapy for Primary Tumor in Stage IV NSCLC

  Speaker: Cheng Hu, MD - THE AFFILIATED HOSPITAL OF GUIZHOU MEDICAL UNIVERSITY, GuiYang
• 12:40pm - 12:50pm ET

  Osimertinib Combined with Stereotactic Body Radiotherapy vs. Osimertinib Alone in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase II Randomized Controlled Trial

  Speaker: Hong Ge, MD - The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou
• 12:50pm - 01:00pm ET

  FLT3 Ligand (CDX-301) and Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer

  Speaker: Nitin Ohri, MD, MS - Albert Einstein College of Medicine, Bronx
• 01:00pm - 01:10pm ET

  Pirfenidone for Reducing Radiation-Induced Lung Injury in Lung Cancer Patients with Prior Receipt of Immune Checkpoint Inhibitors: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial

  Speaker: Guang Han, MD, PhD - Hubei Cancer Hospital, Wuhan
• 01:10pm - 01:20pm ET

  Alteration Subtype is Prognostic of Intracranial Outcome and Predicts the Benefit of Upfront SRS in EGFR-Mutant NSCLC Brain Metastasis

  Speaker: Emily Wo, PharmD - Memorial Sloan Kettering Cancer Center, Middletown Township
• 01:20pm - 01:30pm ET

  Clinical Value and Optimal Timing of Cranial Stereotactic Radiotherapy for Limited Brain Metastases from First-Line Osimertinib-Treated Non-Small Cell Lung Cancer

  Speaker: Silai Yu, - Fudan University Shanghai Cancer Center, Shanghai
• 01:30pm - 01:40pm ET

  Combined Stereotactic Radiotherapy and Immunotherapy Improves Survival in Driver-Gene-Negative NSCLC Patients with Brain Oligometastases: A Phase II Observational Clinical Study

  Speaker: Xiaomei Gong, MD, PhD - ShangHai pulmonary hospital, ShangHai